CJ Whelan

436 total citations
9 papers, 307 citations indexed

About

CJ Whelan is a scholar working on Molecular Biology, Nephrology and Neurology. According to data from OpenAlex, CJ Whelan has authored 9 papers receiving a total of 307 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 2 papers in Nephrology and 2 papers in Neurology. Recurrent topics in CJ Whelan's work include Amyloidosis: Diagnosis, Treatment, Outcomes (9 papers), Lanthanide and Transition Metal Complexes (2 papers) and Parathyroid Disorders and Treatments (2 papers). CJ Whelan is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (9 papers), Lanthanide and Transition Metal Complexes (2 papers) and Parathyroid Disorders and Treatments (2 papers). CJ Whelan collaborates with scholars based in United Kingdom, Pakistan and United States. CJ Whelan's co-authors include Philip N. Hawkins, Marianna Fontana, Helen J. Lachmann, Julian D. Gillmore, Daniel Sado, Anna S Herrey, Viviana Maestrini, Stefan K. Piechnik, Ashutosh Wechalekar and Aviva Petrie and has published in prestigious journals such as European Heart Journal, Journal of Neurology Neurosurgery & Psychiatry and Journal of Neurology.

In The Last Decade

CJ Whelan

9 papers receiving 305 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
CJ Whelan United Kingdom	4	179	129	110	108	54	9	307
Sara Rosengren Sweden	7	290 1.6×	118 0.9×	156 1.4×	73 0.7×	106 2.0×	12	379
Lars Lindsjö Sweden	4	175 1.0×	42 0.3×	96 0.9×	120 1.1×	71 1.3×	7	292
Cristina Quarta United Kingdom	7	305 1.7×	88 0.7×	113 1.0×	40 0.4×	46 0.9×	16	374
Mounira Kharoubi France	11	199 1.1×	91 0.7×	106 1.0×	23 0.2×	65 1.2×	38	278
Sabrina Nordin United Kingdom	10	158 0.9×	212 1.6×	64 0.6×	130 1.2×	192 3.6×	21	453
Yousuf Razvi United Kingdom	10	218 1.2×	47 0.4×	106 1.0×	30 0.3×	38 0.7×	35	288
Imran Uraizee United States	5	228 1.3×	131 1.0×	145 1.3×	19 0.2×	33 0.6×	12	307
Silvia Oghina France	9	178 1.0×	76 0.6×	86 0.8×	16 0.1×	28 0.5×	29	223
Raffaele Martone Italy	11	246 1.4×	87 0.7×	121 1.1×	18 0.2×	51 0.9×	18	277
Franco Bergesio Italy	10	268 1.5×	86 0.7×	128 1.2×	14 0.1×	37 0.7×	11	322

Countries citing papers authored by CJ Whelan

Since Specialization

Citations

This map shows the geographic impact of CJ Whelan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by CJ Whelan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites CJ Whelan more than expected).

Fields of papers citing papers by CJ Whelan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by CJ Whelan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by CJ Whelan. The network helps show where CJ Whelan may publish in the future.

Co-authorship network of co-authors of CJ Whelan

This figure shows the co-authorship network connecting the top 25 collaborators of CJ Whelan. A scholar is included among the top collaborators of CJ Whelan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with CJ Whelan. CJ Whelan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Sachchithanantham, Sajitha, S. Harrison, Richa Manwani, et al.. (2019). PB2127 BORTEZOMIB-HIGH DOSE METHYLPREDNISOLONE OFFERS IMPROVED HAEMATOLOGICAL RESPONSES AND OVERALL SURVIVAL COMPARED TO BORTEZOMIB-DEXAMETHASONE IN SYSTEMIC LIGHT CHAIN AMYLOIDOSIS. HemaSphere. 3(S1). 958–958. 2 indexed citations

2.

Kotecha, Tushar, Andrea Baggiano, Michele Boldrini, et al.. (2018). Assessment of Treatment Response in Cardiac AL Amyloidosis Using CMR Mapping - Results at 3 Months, 6 Months and 1 Year Post-Chemotherapy. UCL Discovery (University College London). 1 indexed citations

3.

Gilbertson, JA, DM Rowczenio, CJ Whelan, et al.. (2015). Diagnostic value of fat aspirates for amyloidosis in 950 patients. Orphanet Journal of Rare Diseases. 10(S1). 4 indexed citations

4.

McColgan, Peter, Steven F. Viegas, Sonia Gandhi, et al.. (2014). Oculoleptomeningeal Amyloidosis associated with transthyretin Leu12Pro in an African patient. Journal of Neurology. 262(1). 228–234. 25 indexed citations

5.

Banypersad, Sanjay M, Marianna Fontana, Viviana Maestrini, et al.. (2014). T1 mapping and survival in systemic light-chain amyloidosis. European Heart Journal. 36(4). 244–251. 268 indexed citations

6.

Carr, Aisling, et al.. (2014). WHY THE LONG FACE?. Journal of Neurology Neurosurgery & Psychiatry. 85(10). e4.145–e4. 1 indexed citations

7.

Gillmore, JD, Helen J. Lachmann, Thirusha Lane, et al.. (2010). CTD versus Mel-Dex as upfront treatment in AL amyloidosis: a matched case-control study. UCL Discovery (University College London). 3 indexed citations

8.

Whelan, CJ, Babita Pawarova, Thirusha Lane, et al.. (2010). Rise in serum NT pro-BNP associated with chemotherapy in patients with AL amyloidosis: implications for organ response assessment. UCL Discovery (University College London). 1 indexed citations

9.

Harding, Stephen, Helen J. Lachmann, JD Gillmore, et al.. (2010). Serum immunoglobulin heavy/light chain ratios (HevyLite) in patients with systemic AL amyloidosis. Clinical Genetics. 84(2). 175–82. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact